# Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

> **NCT01368497** · PHASE3 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 60 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Entecavir and peginterferon

## Key facts

- **NCT ID:** NCT01368497
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-12-23
- **Final completion:** 2016-12-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368497, "Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01368497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*